Study of a new medicine for psychosis in Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a new drug called KarXT to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease. If you or a loved one has Alzheimer's and experiences these symptoms, this study might offer a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 55 and 90 years old.
- You must have a diagnosis of possible or probable Alzheimer's disease.
- You must have had hallucinations or delusions for at least 2 months.
- You need a caregiver or study partner who can help with visits and medication.
- You must have a recent brain scan (MRI or CT) showing no other cause for your symptoms.
- You must be able to walk, with or without a walker or cane.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the long-term safety of an investigational drug called KarXT for people with psychosis caused by Alzheimer's disease. It is for those who have already completed a previous KarXT study and want to continue treatment.
This clinical trial tests an investigational oral medication called KarXT for treating psychosis (hallucinations or delusions) in people with Alzheimer's disease. The study aims to see if the drug can safely reduce these symptoms.
This trial tests a study drug called ML-007C-MA to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease who also have psychosis. If you or your loved one has Alzheimer's and has been experiencing false beliefs or seeing/hearing things that aren't there for at least two months, this study may be an option.
This trial tests an experimental drug, ITI-1284, to see if it can safely reduce psychosis (hallucinations or delusions) in people with Alzheimer's disease. It may be an option for patients who have both Alzheimer's and related psychotic symptoms.
This trial tests a long-term treatment (ML-007C-MA) for people with Alzheimer's disease who have psychosis. It is for those who already completed an earlier study with the same drug and may benefit from continuing it. The goal is to see if ongoing treatment is helpful and safe.
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Hear when a new Psychosis Associated With Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.